Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr285.50 SEK
Change Today +0.50 / 0.18%
Volume 13.0K
BIOGB On Other Exchanges
Symbol
Exchange
OTC US
Berlin
Stockholm
OTC US
As of 11:29 AM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

biogaia ab-b shs (BIOGB) Snapshot

Open
kr285.00
Previous Close
kr285.00
Day High
kr287.50
Day Low
kr278.50
52 Week High
08/18/15 - kr303.00
52 Week Low
10/13/14 - kr150.10
Market Cap
4.9B
Average Volume 10 Days
26.6K
EPS TTM
kr6.44
Shares Outstanding
16.6M
EX-Date
05/8/15
P/E TM
44.3x
Dividend
kr3.46
Dividend Yield
1.75%
Current Stock Chart for BIOGAIA AB-B SHS (BIOGB)

Related News

No related news articles were found.

biogaia ab-b shs (BIOGB) Related Businessweek News

No Related Businessweek News Found

biogaia ab-b shs (BIOGB) Details

BioGaia AB develops, markets, and sells probiotic products with documented health benefits worldwide. It operates through Paediatrics, Adult Health, and New Business segments. The company provides BioGaia ProTectis digestive health probiotic drops, as well as BioGaia ProTectis D3 drops with vitamin D3 containing lactobacillus reuteri protectis for children; and BioGaia ProTectis ORS, a probiotic oral rehydration solution with zinc. It also offers BioGaia ProTectis chewable tablet, a dietary supplement containing lactobacillus reuteri protectis, as well as BioGaia ProDentis oral lozenges, a dietary supplement containing lactobacillus reuteri prodentis for adults and children; BioGaia Gastrus, a probiotic supplement that could enhance treatment of Helicobacter pylori infection; and BioGaia ProTectis straw that provides lactobacillus reuteri protectis to various beverages. In addition, the company offers ProDentis oral health tablet for the treatment of periodontal disease and gingivitis; and component products, which are bacterial cultures of lactobacillus reuteri protectis that are used as ingredients in yoghurt and other dairy products. Further, it provides animal health products. The company sells its products through pharmacies and related outlets. BioGaia AB was founded in 1990 and is headquartered in Stockholm, Sweden.

104 Employees
Last Reported Date: 08/18/15
Founded in 1990

biogaia ab-b shs (BIOGB) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: kr2.3M
Compensation as of Fiscal Year 2014.

biogaia ab-b shs (BIOGB) Key Developments

BioGaia AB Reports Audited Group Earnings Results for the Second Quarter and Six Months and Audited Parent Earnings Results for the Six Months Ended June 30, 2015

BioGaia AB reported audited group earnings results for the second quarter and six months and audited parent earnings results for the six months ended June 30, 2015. For the quarter, on group basis, net sales totaled SEK 134.0 million against SEK 92.4 million last year, an increase of SEK 41.6 million; this corresponds to a rise of 45%, or 31% after adjustment for foreign exchange effects. Operating profit was SEK 42.4 million against SEK 24.9 million last year, an increase of SEK 17.5 million; this corresponds to a rise of 70%, or 33% after adjustment for foreign exchange effects. If costs in the subsidiary IBT are excluded, operating profit for the period was SEK 48.4 million against SEK 26.5 million last year, an increase of SEK 21.9 million (83%). Profit before tax was SEK 43.4 million against SEK 22.4 million last year. Profit attributable to owners of the parent company was SEK 35.7 million against SEK 17.8 million last year. Basic and diluted earnings per share were SEK 2.06 against SEK 1.03 last year. Cash flow from operating activities was SEK 35.4 million against SEK 23.7 million last year. Acquisition of intangible assets was SEK 5.4 million against SEK 1.8 million last year. Purchase of property, plant and equipment was SEK 6.1 million against SEK 5.1 million last year. For the six months, on group basis, net sales totaled SEK 272.9 million against SEK 185.6 million last year. Operating profit was SEK 95 million against SEK 148.7 million last year. Profit before tax was SEK 99.3 million against SEK 147.1 million last year. Profit attributable to owners of the parent company was SEK 78.9 million against SEK 115 million last year. Basic and diluted earnings per share were SEK 4.57 against SEK 6.66 last year. Cash flow from operating activities was SEK 78.8 million against SEK 136.5 million last year. Acquisition of intangible assets was SEK 7.7 million against SEK 1.8 million last year. Purchase of property, plant and equipment was SEK 9.4 million against SEK 9.5 million last year. Return on average equity was 23% against 37% last year. The major part of the company's sales is in foreign currencies, primarily EUR but also USD and JPY. If exchange rates had remained at the level they were during the corresponding period in 2014, sales would have been SEK 24.3 million lower. After making adjustments for foreign exchange effects, sales (excluding license revenue from Nestlé) rose by 34% compared with the corresponding period last year. Of the total investments in property, plant and equipment, SEK 9.3 million against SEK 9.3 million last year, relates to the expansion of the production facility for the subsidiary TwoPac AB. Work on this project commenced during the reporting period. For the six months, on parent basis, net sales totaled SEK 263.4 million against SEK 177.9 million last year. Operating profit was SEK 97.2 million against SEK 151.3 million last year. Profit before tax was SEK 100.1 million against SEK 146.5 million last year. Profit was SEK 80.9 million against SEK 114.9 million last year. Cash flow from operating activities was SEK 72.2 million against SEK 135.8 million last year. Purchase of property, plant and equipment was SEK 0.02 million against SEK 0.06 million last year. Purchase of financial assets was SEK 9.0 million against SEK 4.0 million last year.

Biogaia's Oral Health Probiotic Reduces Candida in the Elderly

BioGaia announced that its oral health probiotic reduces Candida in the elderly. A double-blind, randomised, placebo-controlled study in 215 elderly nursing home residents showed that Lactobacillus reuteri Prodentis reduced the prevalence of oral Candida by more than 50% compared to placebo. After 12 weeks of intervention with two lozenges per day of Lactobacillus reuteri Prodentis there was a statistically significant reduction of 53% in the proportion of patients that had high Candida counts in both saliva and plaque in the probiotic group whereas there was no difference in the placebo group.

BioGaia AB, H1 2015 Earnings Call, Aug 18, 2015

BioGaia AB, H1 2015 Earnings Call, Aug 18, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOGB:SS kr285.50 SEK +0.50

BIOGB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BLIS Technologies Ltd $0.02 NZD -0.002
Danone SA €55.39 EUR +0.14
Oragenics Inc $2.26 USD +0.04
Probi AB kr153.00 SEK -2.50
Yakult Honsha Co Ltd ¥6,630 JPY -150.00
View Industry Companies
 

Industry Analysis

BIOGB

Industry Average

Valuation BIOGB Industry Range
Price/Earnings 43.3x
Price/Sales 10.2x
Price/Book 13.7x
Price/Cash Flow 41.6x
TEV/Sales 9.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOGAIA AB-B SHS, please visit www.biogaia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.